全球临床试验概况报告

OBESITYGLOBAL CLINICAL TRIAL LANDSCAPE (2025) #DYKDid youknow? GLP-1-based therapies, ledby drugs likeWegovyandRybelsus, domi-nate the obesitydrug pipeline TheUnited Statesis one of the leading countriesin the Americas for adult overweightand obesity prevalence Obesityis achronicdiseasecharac-terizedbyexcessivefataccumu-lationthatposessignifi-canthealthrisks TheUK leads major European countriesin adultoverweight and obesity prevalence, followed byRussia and Germany Emergingdual/tri-ple agonistslikeretatrutide andcagrisema reflecta shift towardmulti-target obe-sity treatments TheWestern Pacific regionis witnessing a risingprevalence of obesity, with Australia and NewZealand among the most impacted Southeast Asiashows lower obesity prevalence,with rising rates in Thailand, China, and India,followed by ROW OBESITYTRIAL CONTRIBUTIONS Countries like the United States,Mainland China, South Korea,Germany, and Australia,emerged as top locations forconducting trials. CONTENTS 1. DISEASE BACKGROUND AND EPIDEMIOLOGY2. OBESITY— BIOMARKERS3. STANDARD OF CARE4. GLOBAL CLINICAL TRIAL LANDSCAPE5. DRUG DEVELOPMENT LANDSCAPE6. OBESITY— EVOLVING THERAPEUTIC STRATEGIES7. FUNDING LANDSCAPE8. SWOT ANALYSIS9. APPENDIX 1.DISEASE BACKGROUND AND EPIDEMIOLOGY Disease background Obesity is a chronic disease characterized by excessive fat accumulation that poses significant health risks. Itincreases the likelihood of developing type 2 diabetes, heart disease, musculoskeletal disorders like osteoarthritis,and certain cancers such as breast, ovarian, and colon cancer. Obesity affects daily life by reducing mobility, causingjoint pain, and making tasks like walking or personal care more difficult. It also impacts sleep quality, increasing therisk of conditions like sleep apnea, which leads to poor rest and daytime fatigue, further reducing overall energyand ability to engage in daily activities. Overweight and obesity arise from an imbalance between energy intakeand expenditure, influenced by obesogenic environments, genetic predisposition, and psycho-social factors.Additionally, the absence of early detection and intervention within healthcare systems exacerbates progression toobesity. Obesity is diagnosed primarily by calculating the body mass index (BMI), the ratio of a person’s weight toheight. A BMI of 30 or more in adults indicates obesity. [1] The World Health Organization (WHO) has declared obesity a global health crisis, with one in eight people worldwideliving with obesity in 2022. Since 1990, obesity rates have doubled among adults and quadrupled among adolescents,emphasizing the rapid growth of this epidemic.Obesity, once a concern primarily for high-income countries, nowsignificantly impacts middle-income nations. It has surpassed the prevalence of underweight individuals acrossall regions except South-East Asia, driving a sharp increase in chronic diseases such as heart disease, stroke, anddiabetes. Addressing obesity is now a global public health priority. [1, 2] Epidemiology Globally, close to 900 million adults were affected by obesity in 2022, reflecting a significant rise from previousdecades. This overview highlights the prevalence of obesity across various regions and locations from theWorld Obesity Atlas 2024 report. In 2025, the Region of the Americas (PAHO) had the largest number of adults with obesity globally, with 246million (30%) individuals affected (refer Figure 1). This figure is estimated to rise sharply, nearly 394 million by2035, indicating the escalating obesity crisis in the region. At the country level, the United States reported asignificant prevalence of adult overweight and obesity, affecting approximately 32% and 40% of the population,respectively. Mexico reported that nearly 38% of adults are overweight and 36% are living with obesity, makingit one of the countries with the highest overweight or obesity rates globally. The European region (EURO) is estimated to rank closely behind, with 213 million (21%) adults affected by obesityin 2025. (refer Figure 1). This figure is expected to increase to 263 million by 2035. Within Europe, countries like theUnited Kingdom had an adult overweight and obesity prevalence of approximately 37% and 20% respectively,followed by Russia at 34% and 30%, Germany at 34% and 19%, Belgium at 33% and 16%, and Italy at 32% and10%. The Western Pacific region (WPRO), with an estimated 160 million adults living with obesity in 2025, is projectedto experience a significant rise, reaching 272 million by 2035. In this region, adult overweight and obesityprevalence rates were reported at approximately 34% and 31% in Australia and 33% and 32% in New Zealand. Incomparison, Singapore recorded rates of 28% and 11%, while Vietnam had significantly lower rates at 13% and1%, respectively. In the Eastern Mediterranean region (EMRO), the number of adults living with obesity is estimated to be 134million in 2025, with an expected increase to 212 million by 2035. Com